On 24 April 2007, the Annual General Meeting of H. Lundbeck A/S resolved to reduce the company's share capital by a nominal amount of DKK 29,338,220 by reducing the company's holding of treasury shares. The resolution was announced in the electronic information system of the Danish Commerce and Companies Agency on 2 May 2007, and the statutory notice period has now expired with no claims received. Accordingly, the reduction of the company's share capital was registered with the Danish Commerce and Companies Agency today. Following the reduction of capital, the nominal share capital of H. Lundbeck A/S amounts to 1,034,353,145, equivalent to 206,870,629 shares. The content of this release will have no influence on the Lundbeck Group's financial result for 2007. Lundbeck contacts Investors: Media: Jacob Tolstrup Caroline Broge Investor Relations Manager, Media Relations Manager North America +45 36 43 26 38 +1 201 350 0187 ________________________ Stock Exchange Release No 282 - 3 August 2007 About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com